Semin Neurol 2024; 44(04): 414-418
DOI: 10.1055/s-0044-1787551
Justin C. McArthur
1
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland
,
Derek W. Stitt
2
Division of Neurology Education, Department of Neurology, Mayo Clinic, Rochester, Minnesota
› Author Affiliations
![SFX Search]()
Buy Article Permissions and Reprints
As human beings, our greatness lies not so much in being able to remake the world… as in being able to remake ourselves. – Mahatma Gandhi
Publication History
Article published online:
16 July 2024
© 2024. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
References
1 NCHS Data Brief, No. 491, March. 2024 , Hyattsville, MD: National Center for Health Statistics
2 Center for Behavioral Health Statistics and Quality. 2018 ). 2017 National Survey on Drug Use and Health: Detailed Tables. Accessed May 21, 2024 at:
https://www.cdc.gov/nchs/data/databriefs/db491.pdf
3 Centers for Disease Control and Prevention. Accessed May 21, 2024 at:
https://www.cdc.gov/nchs/data/databriefs/db491.pdf
4
O'Donnell J,
Tanz LJ,
Miller KD.
et al.
Drug overdose deaths with evidence of counterfeit pill use - United States, July 2019-December 2021. MMWR Morb Mortal Wkly Rep 2023; 72 (35) 949-956
5
Marcu J.
The legalization of cannabinoid products and standardizing cannabis-drug development in the United States: a brief report. Dialogues Clin Neurosci 2020; 22 (03) 289-293
6
Jacobus J,
Courtney KE,
Hodgdon EA,
Baca R.
Cannabis and the developing brain: What does the evidence say?. Birth Defects Res 2019; 111 (17) 1302-1307
7 CDC Morbidity and Mortality Weekly Report. . Accessed May 21, 2024 at:
https://search.cdc.gov/search/?query=xylazine&dpage=1
8
McKendrick G,
Stull SW,
Sharma A,
Dunn KE.
Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder. . Semin Neurol 2024 (ahead of publication)
9
Nguyen T,
Ziedan E,
Simon K.
et al
Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic. JAMA Netw Open 2022; 5 (06) e2214765
10
Klausen MK,
Thomsen M,
Wortwein G,
Fink-Jensen A.
The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol 2022; 179 (04) 625-641
11
Mahoney III JJ,
Hanlon CA,
Marshalek PJ,
Rezai AR,
Krinke L.
Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: review of modalities and implications for treatment. J Neurol Sci 2020; 418: 117149
12 Substance Use Disorder Treatment | AMA. Accessed May 21, 2024 at: ama-assn.org
13
Deak JD,
Johnson EC.
Genetics of substance use disorders: a review. Psychol Med 2021; 51 (13) 2189-2200 Erratum in: Psychol Med. 2022 Mar 02;1
留言 (0)